ALLIANCEBERNSTEIN L.P. - SYROS PHARMACEUTICALS INC ownership

SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 66 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q1 2022$63,000
-63.2%
52,800
+0.4%
0.00%
Q4 2021$171,000
-31.6%
52,600
-5.9%
0.00%
Q3 2021$250,000
-18.0%
55,9000.0%0.00%
Q2 2021$305,000
+13.0%
55,900
+54.8%
0.00%
Q1 2021$270,000
-43.5%
36,100
-18.1%
0.00%
Q4 2020$478,000
+9.9%
44,100
-10.4%
0.00%
Q3 2020$435,000
-17.0%
49,2000.0%0.00%
Q2 2020$524,000
+123.0%
49,200
+24.2%
0.00%
Q1 2020$235,000
+11.4%
39,600
+29.8%
0.00%
Q4 2019$211,000
-30.1%
30,500
+4.8%
0.00%
Q3 2019$302,000
+57.3%
29,100
+40.6%
0.00%
Q2 2019$192,000
+31.5%
20,700
+29.4%
0.00%
Q1 2019$146,000
+108.6%
16,000
+28.0%
0.00%
Q4 2018$70,000
-53.0%
12,5000.0%0.00%
Q3 2018$149,000
+26.3%
12,500
+7.8%
0.00%
Q2 2018$118,00011,6000.00%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Flagship Ventures Fund IV General Partner LLC 4,806,656$87,241,00014.92%
Aisling Capital LLC 908,565$16,490,0003.89%
Foresite Capital Management III, LLC 150,000$2,723,0001.87%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,095,220$38,028,0001.50%
Redmile Group, LLC 946,182$15,058,0001.44%
Casdin Capital, LLC 50,000$908,0000.90%
Eventide Asset Management 150,000$2,723,0000.17%
Weiss Multi-Strategy Advisers LLC 45,857$832,0000.06%
Baker Brothers Advisors 204,465$3,711,0000.04%
Alyeska Investment Group, L.P. 70,000$1,271,0000.01%
View complete list of SYROS PHARMACEUTICALS INC shareholders